Related Experiment Video

Updated: Nov 3, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.6K

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets

Shao-Long Chen1, Guo-Ping Wang2, Dan-Rong Shi3

  • 1Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310000, Zhejiang Province, China.

World Journal of Gastroenterology
|June 7, 2021
PubMed

Insights

The receptor protein tyrosine kinase RON is implicated in hepatobiliary and pancreatic cancers. Targeting RON offers a promising therapeutic strategy for these aggressive diseases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The receptor protein tyrosine kinase RON, part of the c-MET family, plays a role in cancer development.
  • Hepatobiliary and pancreatic (HBP) cancers exhibit poor prognoses and high mortality rates.

Purpose of the Study:

  • To investigate the role of aberrant RON expression and signaling in HBP cancer pathogenesis.
  • To explore RON as a potential drug target for novel cancer therapeutics.

Main Methods:

  • Analysis of RON expression and signaling pathways in HBP cancer models.
  • Review of existing and emerging RON-targeted therapeutic strategies.

Main Results:

  • Abnormal RON expression and signaling are identified as key drivers of HBP cancer malignancy.
  • RON is confirmed as a significant mediator of clinical prognosis in HBP cancers.

Conclusions:

  • RON is a critical factor in HBP cancer progression and serves as a viable therapeutic target.
  • Development of RON-targeted therapies, including monoclonal antibodies and small-molecule inhibitors, holds promise for treating HBP cancers.
Keywords:
HepatobiliaryMolecular targeted therapyPancreatic neoplasmsRONSignal transduction

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.4K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.8K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.6K